Macimorelin (Macrilen)

About Cosciens Biopharma

Cosciens Biopharma operates a dual business model combining a commercial natural ingredients division with a pharmaceutical development arm. The company's core technology involves proprietary extraction and manufacturing processes for bioactive compounds from oats, which are sold as active ingredients to major consumer brands and developed for therapeutic uses. Its lead commercial pharmaceutical asset is Macimorelin, an approved oral diagnostic for growth hormone deficiency. Founded in 2020 and led by an interim CEO with a financial background, Cosciens aims to bridge natural product science with clinical applications across dermatology, metabolic health, and diagnostics.

Therapeutic Areas